View all the latest information in myelodysplastic syndromes, arranged by trials and clinical studies. Listed below are recently added trial updates.
What is new for MDS with del(5q)?
During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo,...
Lenalidomide reduces risk of transfusion dependency in lower-risk MDS: Interim results of the Sintra-REV trial
The therapeutic goal for patients with lower-risk myelodysplastic syndrome (MDS) is to...
Imetelstat for patients with highly transfusion-dependent MDS
The initial treatment option for patients with lower-risk MDS is the use of erythropoiesis-stimulating agents (ESAs) with/without other...
Does imetelstat provide transfusion independence in lower-risk MDS?
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Uwe Platzbecker, Leipzig University...
Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast...
P-2001 study: Which patients benefit most from pevonedistat plus azacitidine?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Mikkael Sekeres,...
RIC allo-SCT vs HMA or best supportive care in older patients with high-risk MDS
The BMT CTN designed the phase II randomized trial 1102 (NCT02016781), to assess the benefits of reduced intensity...
When should we consider allo-SCT for patients with MDS?
Corey Cutler talks about the results from the Blood and Marrow Transplant Clinical Trials Network study 1102.
BMT CTN 1102